Robert E. Conway Appointed to ARCA biopharma Board of Directors
BROOMFIELD, Colo. -- September 4, 2013
ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company developing
genetically-targeted therapies for cardiovascular diseases, today announced
that Robert E. Conway, has been appointed to the Company’s Board of Directors.
He will serve on the Audit and Compensation Committees of the Board of
Mr. Conway has over 30 years of executive leadership experience in the
pharmaceutical and biotechnology industries. From 1999 to 2012, he served as
the Chief Executive Officer and member of the Board of Directors of Array
BioPharma, a biopharmaceutical company focused on the discovery, development
and commercialization of targeted small molecule drugs to treat patients
afflicted with cancer and inflammatory diseases. Prior to joining Array, Mr.
Conway was the Chief Operating Officer and Executive Vice President of Hill
Top Research, Inc., from 1996 to 1999. There he managed a network of
company-owned research centers, conducting clinical trials for pharmaceutical
and biotechnology companies. From 1979 until 1996, Mr. Conway held various
executive positions with Corning, Inc., including Corporate Vice President and
General Manager of Corning Hazleton, Inc., a contract research organization.
Mr. Conway serves as the Chairman of Wall Family Enterprise, a leading library
and education supplies company. He is on the Board of Directors of PRA
International, Inc. and eResearch Technology, Inc. In addition, Mr. Conway is
a member of the Strategic Advisory Committee of Genstar Capital, LLC.
“We are honored to have Bob join the ARCA Board of Directors,” said Dr.
Michael R. Bristow, President and Chief Executive Officer of ARCA. “With his
significant experience in leading both drug development efforts and companies
in the biopharmaceutical sector, Bob will be a valuable addition to the ARCA
Board as we continue the development of Gencaro and look to deliver value to
“I am delighted to join the Board of ARCA at this important point in its
development, both for the company and for the cardiology patients we hope to
serve,” said Mr. Conway. “We believe there is an unmet medical need for new
atrial fibrillation treatments. The GENETIC-AF trial, conducted with the
collaboration of Medtronic, will hopefully provide important new data for the
atrial fibrillation community.”
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted therapies for
cardiovascular diseases. The Company's lead product candidate, Gencaro^TM
(bucindolol hydrochloride), is an investigational, pharmacologically unique
beta-blocker and mild vasodilator being developed for atrial fibrillation.
ARCA has identified common genetic variations that it believes predict
individual patient response to Gencaro, giving it the potential to be the
first genetically-targeted atrial fibrillation prevention treatment. ARCA has
a collaboration with Medtronic, Inc. for support of the Phase 2B portion of
the GENETIC-AF trial. For more information please visit www.arcabiopharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements" for purposes of the
safe harbor provided by the Private Securities Litigation Reform Act of 1995.
These statements include, but are not limited to, statements regarding the
potential impact of the GENETIC-AF trial, the potential for genetic variations
to predict individual patient response to Gencaro, Gencaro’s potential to
treat atrial fibrillation, future treatment options for patients with atrial
fibrillation, and the potential for Gencaro to be the first
genetically-targeted atrial fibrillation prevention treatment. Such statements
are based on management's current expectations and involve risks and
uncertainties. Actual results and performance could differ materially from
those projected in the forward-looking statements as a result of many factors,
including, without limitation, the risks and uncertainties associated with:
the Company's financial resources and whether they will be sufficient to meet
the Company's business objectives and operational requirements; results of
earlier clinical trials may not be confirmed in future trials, the protection
and market exclusivity provided by the Company’s intellectual property; risks
related to the drug discovery and the regulatory approval process; and, the
impact of competitive products and technological changes. These and other
factors are identified and described in more detail in ARCA’s filings with the
SEC, including without limitation the Company’s annual report on Form 10-K for
the year ended December 31, 2012, and subsequent filings. The Company
disclaims any intent or obligation to update these forward-looking statements.
ARCA biopharma, Inc.
Investor Relations Advisory Solutions
Derek Cole, 720-940-2163
Press spacebar to pause and continue. Press esc to stop.